James Schaub
2022
In 2022, James Schaub earned a total compensation of $367.2K as EVP and Chief Operating Officer at RVL Pharmaceuticals plc, a 56% decrease compared to previous year.
Compensation breakdown
| Salary | $355,000 |
|---|---|
| Other | $12,200 |
| Total | $367,200 |
Schaub received $355K in salary, accounting for 97% of the total pay in 2022.
Schaub also received $12.2K in other compensation.
Rankings
In 2022, James Schaub's compensation ranked 4,823rd out of 5,736 executives tracked by ExecPay. In other words, Schaub earned more than 15.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,823 out of 5,736 | 16th |
Division Manufacturing | 2,677 out of 3,125 | 14th |
Major group Chemicals And Allied Products | 1,259 out of 1,416 | 11th |
Industry group Drugs | 1,184 out of 1,317 | 10th |
Industry Pharmaceutical Preparations | 866 out of 963 | 10th |
Source: SEC filing on April 24, 2023.
Schaub's colleagues
We found three more compensation records of executives who worked with James Schaub at RVL Pharmaceuticals plc in 2022.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019